Alvotech logo

Alvotech

ALVO | NASDAQ
Chart Builder DCF Calculator
$4.41
+$0.22 (+5.25%)
At close: Nov 16, 2026, 4:00 PM ET
$4.41
$0.00 (-0.11%)
After-hours: Nov 16, 2026, 7:30 PM ET
+5.25%

Rating

Updated: Nov 16, 2026
49.8
Fundamentals Average
Market Sentiment Neutral
Moat Narrow
Sector Rank #288/1021 (Top 28%)

Key Statistics

Market Data

Market Cap $1.57B
1D Range
4.15 4.59
52W Range
3.00 6.15

Valuation (TTM)

PE -5.19
PB -5.88
EV/EBITDA -308.00

Valuation (NTM)

Forward PE 20.30
Forward PEG -2.37
Price Target $8.00
Loading financial charts...

Profile

Alvotech, along with its various subsidiaries, is dedicated to the global development and manufacturing of biosimilar pharmaceuticals. Its product offerings span key therapeutic categories, encompassi...

Sector Healthcare
Employees 1,279
IPO Date Jun 16, 2022
Fiscal Year January - December

Latest News

What Alvotech (ALVO) Said on Its Q3 Earnings Call

4 days ago · marketbeat.com

What Alvotech (ALVO) Said on Its Q3 Earnings Call
Alvotech (ALVO) Reports Q3 Loss, Lags Revenue Estimates

5 days ago · zacks.com

Alvotech (ALVO) Reports Q3 Loss, Lags Revenue Estimates
Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update

5 days ago · globenewswire.com

Alvotech Announces Financial Results for the Nine Months to September 30, 2026, with a Business Update
Will Alvotech (ALVO) Report Negative Earnings Next Week? What You Should Know

13 days ago · zacks.com

Will Alvotech (ALVO) Report Negative Earnings Next Week? What You Should Know
Alvotech: The Market Is Still Pricing The Broken Factory

14 days ago · seekingalpha.com

Alvotech: The Market Is Still Pricing The Broken Factory
Alvotech to Present at Upcoming Investor Conferences in November

15 days ago · globenewswire.com

Alvotech to Present at Upcoming Investor Conferences in November
Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026

20 days ago · globenewswire.com

Alvotech to Report Financial Results for the Nine-Month Period to September 30, 2026
New Strong Sell Stocks for October 21st

27 days ago · zacks.com

New Strong Sell Stocks for October 21st
Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch

28 days ago · globenewswire.com

Alvotech receives FDA approval for new SIMLANDI® manufacturing process that more than doubles output per batch
Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

1 month ago · globenewswire.com

Alvotech and Advanz Pharma announce first known regulatory submission worldwide for proposed biosimilar to Eylea® 8 mg

Earnings

Latest Earnings
Nov 11, 2026
EPS
-$0.03
Miss -0.94%
REV
$111.6M
Miss -9.60%
Next Earnings
Mar 17, 2027
EPS Est
Pro
Rev Est
Pro
Earnings Details ➞

Analyst Summary

# of Analysts
2
Consensus
Buy
Price Target
$8.00
Upside
+81.41%
Buy (2)
Hold (0)
Sell (0)
Analyst Details ➞

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.